文献速递肿瘤 PET/CT放射性药物与辐射防护

利用SPECT成像与非线性房室模型测量抗体在肿瘤中的特异性与非特异性组织摄取

Measurement of specific and nonspecific tissue uptake of antibodies in tumor by SPECT imaging and nonlinear compartmental modeling.
PubMed 文献 · EJNMMI Res · 2025-02-24

本研究在表达人表皮生长因子受体2(HER2)的荷瘤小鼠中,用SPECT成像比较靶向曲妥珠单抗(抗HER2)与非靶向抗gD抗体的体内处置。采用非残留型放射性卤素探针([125I]SIB)与残留型放射性金属螯合物(111In-DOTA)标记,结合房室模型分析抗体在肿瘤与非肿瘤组织中的特异性结合、非特异性内化及分解代谢。结果显示抗HER2抗体存在显著的HER2介导肿瘤摄取与分解代谢,脾脏为非肿瘤组织中分解代谢最高者;细胞相关抗HER2主要为受体结合,给药10 mg/kg后13小时受体占用峰值达35%。

要点

  • SPECT联合非残留与残留探针可区分抗体在肿瘤间质与细胞内的游离、结合及分解代谢状态。
  • 抗HER2抗体在HER2表达肿瘤中显示显著HER2介导的摄取与分解代谢,肿瘤信号高于抗gD对照。
  • 脾脏是两种单克隆抗体在非肿瘤组织中分解代谢最高的器官。

核心结论

  • 研究成功建立成像与建模方法,可在体内随时间捕获抗HER2抗体的受体结合及特异性与非特异性内化。
  • 联合使用非残留型与残留型放射性同位素的SPECT成像有助于表征抗体在间质与细胞内区室的游离、结合和分解代谢等不同生物学状态。
  • 理解肿瘤与非肿瘤组织中抗体内化机制有助于为抗原表达异质性肿瘤的剂量选择提供依据,以优化治疗并减少非特异性毒性。

研究设计与样本

  • 在表达HER2的荷瘤小鼠中开展SPECT成像研究,测量靶向曲妥珠单抗(抗HER2)与非靶向抗gD抗体的全身处置动力学。
  • 小鼠接受[125I]SIB(非残留型)或111In-DOTA(残留型放射性金属螯合物)标记的上述分子。

主要发现

  • SPECT数据证实抗HER2存在显著的HER2介导肿瘤摄取与分解代谢,表现为111In-DOTA-抗HER2信号随时间高于111In-DOTA-抗gD及相应的[125I]SIB标记分子。
  • [125I]SIB-抗HER2的肿瘤信号仍明显高于[125I]SIB-抗gD,表明肿瘤间质区室中存在有意义的完整抗HER2池。
  • 在所有非肿瘤组织中,脾脏对两种单克隆抗体的分解代谢最高。
  • SPECT数据的房室模型分析显示,细胞相关抗HER2主要为受体结合,给药10 mg/kg后13小时受体占用峰值达35%,游离与胞饮单克隆抗体极少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Understanding the mechanisms driving specific and nonspecific tissue uptake of antibodies can inform protein engineering strategies that maximize therapeutic efficacy in target tissues while minimizing off-target tissue toxicities. While in vitro cell assays are typically used to study these internalization mechanisms, there are few methods readily available to evaluate these pathways in vivo. Single photon emission computed tomography (SPECT) imaging with a non-residualizing radiohalogen probe can measure total levels of intact antibody, and a residualizing radiometal-chelate probe, in combination with a non-residualizing probe, can measure catabolized antibody associated with receptor-mediated and nonspecific internalization processes. Here, we describe a SPECT imaging study in human epidermal growth factor receptor 2 (HER2)-expressing tumor-bearing mice aimed at measuring whole body disposition kinetics of tumor-targeting trastuzumab (anti-HER2) and non-targeting (anti-gD) antibodies. Mice received these molecules labeled with either a non-residualizing prosthetic group ([125I]SIB) or with a residualizing radiometal-chelate (111In-DOTA). RESULTS: SPECT imaging data confirmed significant HER2-mediated tumor uptake and catabolism of anti-HER2, evidenced by the high 111In-DOTA-anti-HER2 signal over time relative to 111In-DOTA-anti-gD and the respective [125I]SIB-labeled molecules. [125I]SIB-anti-HER2 still showed noticeably higher tumor signal than [125I]SIB-anti-gD, demonstrating a meaningful pool of intact anti-HER2 in the interstitial tumor compartment. Spleen showed the greatest catabolism of both mAbs amongst all non-tumor tissues. Compartmental modeling of the SPECT data demonstrated that cell-associated anti-HER2 was primarily receptor-bound, with a peak receptor occupancy of 35% at 13 h post administration of a 10 mg/kg dose, with minimal free and pinocytosed mAb. CONCLUSION: Here, we successfully developed an imaging and modeling approach to capture anti-HER2 antibody receptor binding as well as specific and nonspecific internalization over time in vivo. These data and analyses demonstrate the power of SPECT imaging using both non-residualizing and residualizing radioisotopes to better characterize the different biological states (free, bound, and catabolized) of antibodies within interstitial and intracellular compartments. Understanding these distinct antibody internalization mechanisms in tumor and non-tumor tissues enables more informed decisions on dose selection to optimize treatment of tumors with heterogeneous antigen expression while minimizing nonspecific toxicities.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Cho N, Ho J, Rosario GD, et al. Measurement of specific and nonspecific tissue uptake of antibodies in tumor by SPECT imaging and nonlinear compartmental modeling. EJNMMI Res. 2025. PMID: 39994098. doi:10.1186/s13550-025-01207-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。